You are here

Programme 2

Day 2 Morning Plenary

Pharma Presentation
09.00
Speaker Name:
Johan Luthmann
Company:
Merck
Position:
Senior Program Leader Neuroscience & Opthalmology R&D, Franchise Integrator
Presentation Subject:

 

Beyond Oncology: Advancement of therapeutics and Diagnostics in Alzheimer’s disease, and Progressing Biomarkers in Neuroscience

Partner Presentation
09.30
Speaker Name:
Mark van Mierle
Company:
Elsevier
Position:
Managing Director
Presentation Subject:

Presentation title & abstract pending

Industry Expert
10.00
Speaker Name:
Prakhar Verma
Company:
Frost & Sullivan
Position:
Senior Industry Analyst
Presentation Subject:

 

Effective strategies for increasing external R&D to leverage outside expertise and meet economic challenges

Partner Presentation
10.30
Speaker Name:
Speaker to be announced
Company:
ACD Labs
Presentation Subject:

Presentation title & abstract pending

Morning Refreshments & 1-2-1 Meetings
11.00
Stream 1 - Advanced Personalised Medicine & Diagnostics
Pharma Presentation
11:30
Speaker Name:
Robert Beckman
Company:
Daiichi Sankyo
Position:
Executive Director Clinical Biomarker and Diagnostics
Presentation Subject:

 

Best Practice in Integration of State-of-the-Art Biomarker Strategies

Pharma Presentation
12:00
Speaker Name:
Oscar Puig
Company:
Roche
Position:
Biomarker and Experimental Medicine Leader, Translational Clinical Research Center
Presentation Subject:

Exploring the Next Wave in Clinically Effective Markers for Oncology

Interactive Panel
12:30
Speaker Name:
Panelists to be announced
Presentation Subject:

Exploring the Past, Present and Future of Oncology Genomics

Networking Lunch
13:00
Pharma Presentation
14.00
Speaker Name:
Jonathan Pan
Company:
GlaxoSmithKline
Position:
Director, Oncology Companion Diagnostics & Disease Strategy
Presentation Subject:

 

Partnerships, Infrastructure, Innovation: Embracing New Paradigms & Making REAL Headway in Dx Partnerships

Pharma Presentation
14.30
Speaker Name:
Michael Burczynski
Company:
Bristol-Myers Squibb
Position:
Executive Director, Head of Integrated Biomarker Technologies
Presentation Subject:

 

Robust Biomarker & Diagnostic Strategies for the Advancement of Individualized Oncology Therapeutics

Afternoon Refreshments & 1-2-1 Meetings
15.00
Stream 2 - Access the Drug Discovery Goldmine
Pharma Presentation
11.30
Speaker Name:
David Sherris
Company:
Paloma Pharmaceuticals
Position:
President & CEO
Presentation Subject:

 

Solving the early-phase conundrum: Achieving greater quality data through pushing development further into statistical POC

Academic Presentation
12.00
Speaker Name:
Michelle Palmer
Company:
Broad Institute of Harvard & MIT
Position:
Director, Discovery & Preclinical Research
Presentation Subject:

 

Integrating Novel Technologies to Identify Small-Molecules Driving Translational Research and Therapeutics in Cardiovascular Disease

Pharma Presentation
12.30
Speaker Name:
William Loging
Company:
Boehringer Ingelheim
Position:
Director, Scientific Knowledge Discovery
Presentation Subject:

Innovating and strengthening discovery efforts through robust computational/bioinformatic approaches


Networking Lunch
13:00
Pharma Presentation
14.00
Speaker Name:
Speaker to be announced
Presentation Subject:

 

Addressing Key Mechanisms of Action in Novel Drug Design

Interactive Panel
14.30
Speaker Name:
Panelists to be announced
Presentation Subject:

PANEL: Exploring best integrated drug discovery and drug development solutions from target validation to clinical POC studies

Afternoon Refreshments & 1-2-1 Meetings
15.00

.
 

Day 2 Afternoon Plenary
 

Interactive Oxford-Style Debate
15.30
Presentation Subject:

 

OXFORD STYLE DEBATE

Diagnosing The Decline In Pharmaceutical R&D Efficiency 

Motions: 

More information will help us if we learn to integrate it properly

Emerging Biotech will set a new standard in R&D productivity

Big Pharma 'Culture' is at the heart of R&D decline

Close of Conference
16.30